Shimla Online

Chemotherapy-Induced Nausea and Vomiting (CINV) Market Analysis, Leading Companies, Emerging Drugs and Epidemiology Forecast

 Breaking News
  • No posts were found

Chemotherapy-Induced Nausea and Vomiting (CINV) Market Analysis, Leading Companies, Emerging Drugs and Epidemiology Forecast

September 10
20:05 2020
Chemotherapy-Induced Nausea and Vomiting (CINV) Market Analysis, Leading Companies, Emerging Drugs and Epidemiology Forecast

DelveInsight Business Research LLP
DelveInsight’s “Chemotherapy-Induced Nausea and Vomiting (CINV) Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the Chemotherapy-Induced Nausea and Vomiting (CINV), historical and forecasted epidemiology as well as the Chemotherapy-Induced Nausea and Vomiting (CINV) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Chemotherapy Induced Nausea and Vomiting (CINV) is used to describe two of the most common and distressing side effects of cancer chemotherapy, i.e., nausea and vomiting. They cause a significant negative impact on the patients’ quality of life and on their ability to comply with therapy. Nausea and vomiting can also result in anorexia, decreased performance status, metabolic imbalance, wound dehiscence, esophageal tears, and nutritional deficiency.

Risk factors for Chemotherapy Induced Nausea and Vomiting (CINV) can be divided into patient-specific and treatment-specific risk factors. Female sex and history of motion or morning sickness are clear risk factors for nausea and vomiting. Younger age has also been correlated with increased risk, although this may be explained by the more aggressive chemotherapy regimens that tend to be administered to younger patients who have more aggressive diseases. Finally, alcohol intake tends to be inversely correlated with the risk of developing CINV. Many factors contribute to the treatment-specific risk, including the emetogenicity of the agents being used, the dose and schedule of each agent, and in the case of radiation-induced or postoperative nausea, the site of radiation or surgery.

Get FREE sample copy at: 

https://www.delveinsight.com/sample-request/chemotherapy-induced-nausea-and-vomiting-market

 

chemotherapy-induced-nausea-and-vomiting-cinv-market-size-share-trends-growth-trends-analysis

The Chemotherapy-Induced Nausea and Vomiting (CINV) market report also covers emerging drugs, current treatment practices, Chemotherapy-Induced Nausea and Vomiting (CINV) market share of the individual therapies, current and forecasted Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size from 2017 to 2030 segmented by seven major markets. 

The report provides a detailed current Chemotherapy-Induced Nausea and Vomiting (CINV) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market. 

 

Chemotherapy-Induced Nausea and Vomiting (CINV) Market Key Facts

Among the CINV patients, female patients have more severe and frequent chemotherapy-induced nausea and vomiting than do male patients.

Despite the extensive use of antiemetics, CINV continues to be reported by up to 70% of adult patients receiving moderately and highly emetogenic chemotherapy agents and 58% of school age and adolescent age children receiving highly emetogenic chemotherapy. (Julie et. al.,2010)

As per Ruggiero A et al. (2018), CINV has been estimated to occur in up to 70% of the paediatric population undergoing chemotherapy, which is similar to prevalence rates described in adult patients, for whom nausea and vomiting are described as the first and third most distressing chemotherapy adverse effects, with a prevalence of approximately 60% and 72%, respectively.

 

Key Benefits of Chemotherapy-Induced Nausea and Vomiting (CINV) Market Report

  • Chemotherapy-Induced Nausea and Vomiting (CINV) market report provides an in-depth analysis of Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major market i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.

  • The Chemotherapy-Induced Nausea and Vomiting (CINV) market report will help in developing business strategies by understanding the Chemotherapy-Induced Nausea and Vomiting (CINV) Market trends & developments, key players and future market competition that will shape and drive the Chemotherapy-Induced Nausea and Vomiting (CINV) market in the upcoming years.

  • The Chemotherapy-Induced Nausea and Vomiting (CINV) market report covers Chemotherapy-Induced Nausea and Vomiting (CINV) current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.

  • The report provides a detailed assessment of the Chemotherapy-Induced Nausea and Vomiting (CINV) market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population,  comparative analysis of pipeline products with detailed clinical profiles, and other factors. 

 

Chemotherapy-Induced Nausea and Vomiting (CINV) Market

Among patients with cancer, chemotherapy-induced nausea and vomiting (CINV) is a common adverse effect that not only impacts quality of life, but also treatment outcomes. The precise physiologic mechanisms responsible for acute and delayed CINV continue to be elucidated and have provided an opportunity to develop antiemetic therapies targeting these pathways. It is critical to focus on developing a better understanding of the mechanisms underlying nausea, anticipatory symptoms, and delayed symptoms. Perhaps this area of research has been hampered due to the lack of animal models for nausea.

Chemotherapy-Induced Nausea and Vomiting market size is anticipated to Increase during the study period, 2017–2030. The key driver for the surge in market size is the rise in the number of Incident cases of Chemotherapy-Induced Nausea and Vomiting patients in 7MM.

The Chemotherapy-Induced Nausea and Vomiting (CINV) market outlook section of the report helps to build the detailed comprehension of the historic, current and forecasted Chemotherapy-Induced Nausea and Vomiting (CINV) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology. 

The report gives a thorough detail of Chemotherapy-Induced Nausea and Vomiting (CINV) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders. 

 

Chemotherapy-Induced Nausea and Vomiting (CINV) Epidemiology

The Chemotherapy-Induced Nausea and Vomiting (CINV) epidemiology section covers insights about historical and current Chemotherapy-Induced Nausea and Vomiting (CINV) patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

 

Chemotherapy-Induced Nausea and Vomiting (CINV) Drugs Uptake and Key Market Players

The Chemotherapy-Induced Nausea and Vomiting (CINV) Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chemotherapy-Induced Nausea and Vomiting (CINV) market or expected to get launched in the market during the study period. The analysis covers Chemotherapy-Induced Nausea and Vomiting (CINV) market uptake by drugs; patient uptake by therapies; and sales of each drug.    

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The dynamics of Chemotherapy-Induced Nausea and Vomiting (CINV) market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the diseases, incremental healthcare spending across the world, and the expected launch of emerging therapies during the forecast period of 2020–2030.

Some of the key companies in the Chemotherapy-Induced Nausea and Vomiting (CINV) market includes:
Helsinn Healthcare
Heron Therapeutics
Novartis Therapeutics
Acacia Pharma
And many others.

 

Drugs Covered
APD403
Fosnetupitant IV
Fosnetupitant/palonosetron oral suspension (for pediatric patients)
And many others.

 

Table of Content

1. Key Insights

2. Executive Summary 

3. Chemotherapy-Induced Nausea and Vomiting (CINV) Competitive Intelligence Analysis

4. Chemotherapy-Induced Nausea and Vomiting (CINV) Market Overview at a Glance

5. Chemotherapy-Induced Nausea and Vomiting (CINV) Disease Background and Overview

6. Chemotherapy-Induced Nausea and Vomiting (CINV) Patient Journey

7. Chemotherapy-Induced Nausea and Vomiting (CINV) Epidemiology and Patient Population

8. Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment Algorithm, Current Treatment, and Medical Practices

9. Chemotherapy-Induced Nausea and Vomiting (CINV) Unmet Needs

10. Key Endpoints of Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment

11. Chemotherapy-Induced Nausea and Vomiting (CINV) Marketed Products

12. Chemotherapy-Induced Nausea and Vomiting (CINV) Emerging Therapies

13. Chemotherapy-Induced Nausea and Vomiting (CINV) Seven Major Market Analysis

14. Attribute Analysis

15. Chemotherapy-Induced Nausea and Vomiting (CINV) Market Outlook (7 major markets)

16. Chemotherapy-Induced Nausea and Vomiting (CINV) Access and Reimbursement Overview

17. KOL Views on the Chemotherapy-Induced Nausea and Vomiting (CINV) Market.

18. Chemotherapy-Induced Nausea and Vomiting (CINV) Market Drivers

19. Chemotherapy-Induced Nausea and Vomiting (CINV) Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

 

Related Reports

Chemotherapy Induced Nausea and Vomiting Epidemiology Forecast to 2030

DelveInsight’s Chemotherapy Induced Nausea and Vomiting  Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Chemotherapy Induced Nausea and Vomiting in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

 

Chemotherapy Induced Nausea and Vomiting Pipeline Insights, 2020

Chemotherapy Induced Nausea and Vomiting Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Chemotherapy Induced Nausea and Vomiting market.

 

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Related Articles